Osteonecrosis News and Research

RSS

Novel bioengineering technique could help repair bone defects

Researchers have developed a bone engineering technique that uses stem cells to improve bone grafts for the treatment of bone injury or disease.

18 Jul 2018

A systematic approach towards diagnosis and treatment of rheumatoid arthritis

Rheumatoid Arthritis: A systematic approach (edited by Dr. Syuichi Koarada) comprehensively covers each aspect of the pathology, diagnosis and treatment of rheumatoid arthritis.

26 Jun 2018

$Study finds incidence of fractures in 15% of osteoporosis patients who take 'drug holidays'$

Study finds incidence of fractures in 15% of osteoporosis patients who take 'drug holidays'

Patients who take osteoporosis drugs for long periods typically are advised to temporarily discontinue the drugs to prevent rare but serious side effects to the jaw and thighs.

4 May 2018

Hip replacement surgery associated with increased life expectancy, study reports

Hip replacement surgery not only improves quality of life but is also associated with increased life expectancy, compared to people of similar age and sex, reports a study in Clinical Orthopaedics and Related Research, a publication of The Association of Bone and Joint Surgeons.

28 Feb 2018

FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence

The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

17 Nov 2017

Comprehensive surgical options could benefit osteoporosis patients with medication-related jaw necrosis

Osteoporosis patients who suffer drug side effects that result in painful exposed bone in the jaw could benefit if they are treated with one of the more comprehensive surgical options that could lower the risk of relapse and repeat surgery, according to a study published in the July issue of the Journal of Oral and Maxillofacial Surgery.

5 Jul 2017

Amgen, UCB present romosozumab Phase 2 results at ENDO 2017

Amgen and UCB today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an investigational agent for postmenopausal women with osteoporosis.

3 Apr 2017

New article outlines identical symptoms linked to hip and spine pain

Many patients live with low back pain that radiates to the buttock, groin, thigh, and even knees. The challenge for patients, and often their doctors, is determining the origin of the pain -- the hip, the spine, or both.

7 Feb 2017

Scientists discover novel genetic mutation linked to osteonecrosis of femoral head

Scientists at the Research Institute of McGill University Health Centre have discovered a new genetic mutation linked to osteonecrosis of the hip, specifically the femoral head - the spherical-shaped mass at the top of the femur.

14 Jul 2016

High doses of commonly-used chemotherapy drug may increase survival rate of ALL patients

With a cure rate approaching 90 percent, acute lymphoblastic leukemia (ALL) - the most common type of childhood cancer - is often hailed as one of the "success stories" of modern cancer treatment. But up to 20 percent of patients with a high risk of relapse are not cured. That could change with the results from a clinical trial co-led by investigators from NYU Langone Medical Center, which shows giving high doses of a commonly-used chemotherapy drug increases the survival rate for these patients.

26 Apr 2016

Romosozumab for postmenopausal women with osteoporosis meets co-primary endpoints in Phase 3 study

Amgen and UCB today announced top-line results from the Phase 3 placebo-controlled FRActure study in postmenopausal woMen with ostEoporosis (FRAME).

22 Feb 2016

$New editorial calls on doctors to individualize treatment decisions based on patients' fracture risk$

New editorial calls on doctors to individualize treatment decisions based on patients' fracture risk

A new editorial published by an International Osteoporosis Foundation Working Group urges physicians to individualize treatment decisions based on their patients' fracture risk, rather than automatically interrupting or stopping bisphosphonate therapy after five or three years.

5 Jan 2016

Research reveals genetic variants linked to treatment-related complications in children with blood diseases

Research to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition reveals genetic variants that are associated with disease severity and treatment-related complications in children with blood diseases.

7 Dec 2015

Genetic variations associated with increased risk for osteonecrosis in young ALL patients

Variations in genes involved in normal bone development are associated with an 8- to 15-fold increased risk for osteonecrosis in young patients with acute lymphoblastic leukemia (ALL), according to research led by St. Jude Children's Research Hospital and Children's Oncology Group investigators.

7 Dec 2015

$Bisphosphonate drugs linked to greater risk of atypical hip fractures$

Bisphosphonate drugs linked to greater risk of atypical hip fractures

The use of bisphosphonates, a group of drugs used to prevent hip breakages in women with osteoporosis, is associated with an increased risk of atypical fractures in this joint, understood as those that occur in less frequent locations.

22 Sep 2015

Amgen's XGEVA (denosumab) receives FDA approval for treatment of hypercalcemia of malignancy

Amgen today announced that the U.S. Food and Drug Administration has approved a new indication for XGEVA (denosumab) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy.

8 Dec 2014

Study explores use of bisphosphonates for men receiving androgen deprivation therapy

Although some guidelines recommend use of bisphosphonates (a class of drugs used to strengthen bone) for men on androgen deprivation therapy, an analysis finds that prescriptions for these drugs remains low, even for those men at high risk of subsequent fractures, according to a study in the December 3 issue of JAMA.

3 Dec 2014

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S.

6 Oct 2014

Activity level predicts how well patients recover from injuries after treatment

According to a literature review in the July issue of the Journal of the American Academy of Orthopaedic Surgeons, patients' activity level is a strong predictor for how well they will do with certain treatments and how well they recover from injuries after treatment. Patients are encouraged to ask their orthopaedic surgeon if activity level is an important factor in their treatment decision.

23 Jul 2014

Medac Pharma's Rasuvo injection gets FDA approval for RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced that the U.S. Food and Drug Administration has approved Rasuvo, a subcutaneous injectable methotrexate (MTX) therapy delivered in an auto-injector for rheumatoid arthritis (RA), polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis.

14 Jul 2014